Gufic Biosciences Valuation

Q: What is the Fair Price of 509079 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

509079 (₹407.85) is trading above our estimate of [[fair value]] (₹1.84)

Is 509079 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 509079 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 509079 (₹407.85) is trading above our estimate of fair value (₹1.84)

Significantly Below Fair Value: 509079 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 509079?

Key metric: As 509079 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 509079. This is calculated by dividing 509079's market cap by their current earnings.
What is 509079's PE Ratio?
PE Ratio	48.2x
Earnings	₹849.28m
Market Cap	₹42.20b

509079 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.6x
Enterprise Value/EBITDA	32.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 509079's PE Ratio compare to its peers?

The above table shows the PE ratio for 509079 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	37.8x
524348 Aarti Drugs	27.5x	31.5%	₹41.9b
JSLL Jeena Sikho Lifecare	57x	n/a	₹47.7b
500288 Morepen Laboratories	30.6x	n/a	₹40.1b
SUPRIYA Supriya Lifescience	35.9x	14.3%	₹56.6b
509079 Gufic Biosciences	48.2x	n/a	₹42.2b

Price-To-Earnings vs Peers: 509079 is expensive based on its Price-To-Earnings Ratio (48.2x) compared to the peer average (37.8x).

Price to Earnings Ratio vs Industry

How does 509079's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$72.78m
524652 Ind-Swift	2x	n/a	US$13.52m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 509079 is expensive based on its Price-To-Earnings Ratio (48.2x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 509079's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

509079 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	48.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 509079's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

-3.5%

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

-1.3%

-16.9%